Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers.

European journal of human genetics : EJHG - 1 Aug 2018

Ibrahim Isaura, Sibinga Mulder Babs G, Bonsing Bert, Morreau Hans, Farina Sarasqueta Arantza, Inderson Akin, Luelmo Saskia, Feshtali Shirin, Potjer Thomas P, de Vos Tot Nederveen Cappel Wouter, Wasser Martin, Vasen Hans F A

Abstract excerpt

CDKN2A-p16-Leiden mutation carriers have a substantial risk of developing pancreatic ductal adenocarcinoma (PDAC). One of the main clinical features of hereditary cancer is the development of multiple cancers. Since 2000, we have run a surveillance program for CDKN2A-p16-Leiden mutation carriers. The patients are offered a yearly MRI with optionally endoscopic ultrasound. In patients with a confirmed lesion,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p16

Share to Genetic Predisposition to Disease

Share to Heterozygote

Share to Mutation

Share to Pancreatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 29769629
DOI: 10.1038/s41431-018-0170-y
PMCID: PMC6057932

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risk of multiple pancreatic cancers in CDKN2A-p16-Leiden mutation carriers.PMID 29769629Read ↗

High Growth Rate of Pancreatic Ductal Adenocarcinoma in CDKN2A-p16-Leiden Mutation Carriers.Semantic proximity Read ↗

Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion ofp16 (p16-Leiden)Semantic proximity Read ↗

Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.Semantic proximity Read ↗

Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 p16LeidenSemantic proximity Read ↗

Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).Semantic proximity Read ↗

Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).Semantic proximity Read ↗

Multiple primaries in pancreatic cancer patients: indicator of a genetic predisposition?Semantic proximity Read ↗

Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.Semantic proximity Read ↗

Double germline mutations in APC and BRCA2 in an individual with a pancreatic tumor.Semantic proximity Read ↗

Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation.Semantic proximity Read ↗

CDKN2A germline mutations in familial pancreatic cancer.Semantic proximity Read ↗

Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.